Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.85 USD
Change Today -0.019 / -2.19%
Volume 49.1K
DMPI On Other Exchanges
As of 8:10 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

delmar pharmaceuticals inc (DMPI) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/6/14 - $1.02
52 Week Low
08/27/15 - $0.43
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

delmar pharmaceuticals inc (DMPI) Related Businessweek News

No Related Businessweek News Found

delmar pharmaceuticals inc (DMPI) Details

DelMar Pharmaceuticals, Inc. focuses on the discovery and development of medicines with the potential to treat cancer patients who have failed modern targeted or biologic therapy. Its principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-cancer activity in patients with glioblastoma multiforme, a form of brain cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the manufacture and sale of VAL-083 in China. DelMar Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Vancouver, Canada.

4 Employees
Last Reported Date: 09/3/15
Founded in 2010

delmar pharmaceuticals inc (DMPI) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $180.0K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $150.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $175.0K
Compensation as of Fiscal Year 2015.

delmar pharmaceuticals inc (DMPI) Key Developments

Del Mar Pharmaceuticals Inc. to Present Data on the Potential of Val-083 in the Treatment of Pediatric Brain Tumors

Del Mar Pharmaceuticals Inc. announced that it will present an abstract entitled, Dianhydrogalactitol (VAL-083) Offers Potential Therapeutic Alternatives in the treatment of Pediatric Brain Tumors, at the American Association for Cancer Research (AACR) Advances in Pediatric Research. The company presented an update from its ongoing multicenter Phase I/II clinical study for the treatment of adult refractory glioblastoma multiforme (GBM) at the GBM2015 Conference. VAL-083 demonstrated a favorable safety-profile and doses up to 40mg/m 2 were well tolerated by patients receiving three daily doses in a 21 day cycle. A sub-group analysis of patients receiving up to 5 mg/m 2 daily x 3 every 21 days (low dose) versus those patients receiving 30mg/m2 or 40mg/m2 (high dose) of VAL-083 demonstrated a dose-related survival benefit in adult GBM patients failing standard front-line therapy and bevacizumab.

Del Mar Pharmaceuticals Inc. Presents at Virtual Investor Conference, Oct-01-2015 10:00 AM

Del Mar Pharmaceuticals Inc. Presents at Virtual Investor Conference, Oct-01-2015 10:00 AM.

Del Mar Pharmaceuticals Inc. Presents at GCFF Toronto Conference 2015, Sep-26-2015 04:15 PM

Del Mar Pharmaceuticals Inc. Presents at GCFF Toronto Conference 2015, Sep-26-2015 04:15 PM. Venue: Courtyard by Marriott, Toronto NorthEast, 7095 Woodbine, Markham, ON L3R 1A3, Canada. Speakers: Jeffrey A. Bacha, Co-Founder, Chairman, Chief Executive Officer and President.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DMPI:US $0.85 USD -0.019

DMPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DMPI.
View Industry Companies

Industry Analysis


Industry Average

Valuation DMPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 146.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DELMAR PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at